Compare TUYA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | DVAX |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2004 |
| Metric | TUYA | DVAX |
|---|---|---|
| Price | $2.20 | $15.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $3.49 | ★ $26.50 |
| AVG Volume (30 Days) | 881.9K | ★ 3.0M |
| Earning Date | 11-24-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $319,363,000.00 | ★ $330,514,000.00 |
| Revenue This Year | $8.84 | $24.63 |
| Revenue Next Year | $12.17 | $15.85 |
| P/E Ratio | $28.75 | ★ N/A |
| Revenue Growth | 13.66 | ★ 26.73 |
| 52 Week Low | $1.57 | $9.20 |
| 52 Week High | $4.63 | $15.49 |
| Indicator | TUYA | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 89.09 |
| Support Level | $2.18 | $10.78 |
| Resistance Level | $2.31 | $15.49 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.00 | 0.44 |
| Stochastic Oscillator | 25.81 | 97.84 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.